The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels - Heard on the Street — WSJ

By David WainerThe excitement surrounding Moderna and Merck's personalized mRNA cancer vaccine added more than $50 billion in combined market value for the two drug companies. But it is also creating a gold rush in a growing corner of healthcare: tumor sequencing.Personalized cancer therapies requi…